MML Investors Services LLC Purchases Shares of 2,274 Vaxcyte, Inc. (NASDAQ:PCVX)

MML Investors Services LLC purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 2,274 shares of the company’s stock, valued at approximately $260,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its holdings in Vaxcyte by 68.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after buying an additional 8,685 shares during the last quarter. Natixis Advisors LLC lifted its stake in Vaxcyte by 61.1% in the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after acquiring an additional 8,606 shares during the last quarter. Tri Locum Partners LP bought a new position in shares of Vaxcyte in the 2nd quarter valued at about $8,559,000. Hsbc Holdings PLC acquired a new position in shares of Vaxcyte during the 2nd quarter worth about $1,053,000. Finally, Lisanti Capital Growth LLC raised its holdings in shares of Vaxcyte by 68.1% in the 3rd quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock valued at $3,715,000 after purchasing an additional 13,175 shares during the period. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $85.91 on Thursday. Vaxcyte, Inc. has a one year low of $53.83 and a one year high of $121.06. The firm has a market cap of $10.71 billion, a price-to-earnings ratio of -18.68 and a beta of 0.94. The stock’s fifty day moving average price is $96.95 and its two-hundred day moving average price is $92.58.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the business earned ($0.91) EPS. On average, equities analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Insider Transactions at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 7,098 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $109.21, for a total transaction of $775,172.58. Following the sale, the chief executive officer now directly owns 138,581 shares in the company, valued at $15,134,431.01. This represents a 4.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00. Following the completion of the transaction, the chief financial officer now owns 109,491 shares of the company’s stock, valued at $9,720,610.98. The trade was a 6.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 117,830 shares of company stock valued at $12,383,030. 3.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently commented on PCVX. Bank of America boosted their price target on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Mizuho boosted their target price on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. The Goldman Sachs Group initiated coverage on Vaxcyte in a report on Friday, December 20th. They set a “buy” rating and a $135.00 price target for the company. BTIG Research upped their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, Jefferies Financial Group increased their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.